NICE says case for Opdivo to treat lung cancer is not clear cut

14 October 2016

The National Institute for Health and Care Excellence (NICE) has asked Bristol-Myers Squibb (NYSE: BMY) to set out a case for including its Opdivo (nivolumab) in the Cancer Drugs Fund (CDF).

The medicines cost-effectiveness watchdog for England and Wales NICE’s appraisal committee concluded that nivolumab was not cost-effective for all patients with squamous and non-squamous advanced non-small-cell lung cancer but it did appear to benefit some more than others. The appraisal committee agreed that it was important to explore this benefit.

In trials, people taking nivolumab who had more PD-L1 on their cancer cells lived up to seven months longer than those with less. The committee have asked Bristol-Myers Squibb to make their case to include nivolumab in the CDF so more information can be gathered on its cost-effectiveness in patients with tumour PD-L1 levels of 10% or more.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK